Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Forest Laboratories Inc. v. Teva Pharmaceuticals USA Inc., No. 16-2550 (Fed. Cir. Dec. 11, 2017)

Affirmed
Indefiniteness Claim Construction
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 16-2550
Also Docketed
No. 16-2553 (consolidated; same document)
Decided
December 11, 2017
Judge
Taranto, J.
Document
Nonprecedential Opinion
Length
19 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Forest Laboratories, Inc.; For est Laboratories Hol d- ings, Ltd.; and Adamas Pharmaceuticals, Inc. (collective- ly, Forest) filed patent infringement action s against Teva Pharmaceuticals USA, Inc., in the U.S. District Cou rt for the District of Delaware . During claim construction, t he district court determined that all of the asserted patent claims are invalid for indefinit eness and on that basis entered judgment against Forest.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error